In the neoadjuvant chemotherapy subgroup, the PFS and OS curves after 20 and 30 months respectively showed a trend towards gradual distinction favoring HIPEC, allowing the authors to conclude that more long-term follow-up is needed to confirm the impact of HIPEC in this population [ 35 ].
2
—
—
The sentences
Though criticisms are present in many of the trials, there appears to be a clear trend towards survival benefit with its use while maintaining a well-tolerated side effect profile.